发明名称 Derivatives of aminoindazoles, method of preparation and intermediates of the method as drugs pharmaceutical compounds containing
摘要 3-Acylamino-1H-indazole derivatives (I) are new. Indazole derivatives of formula (I) (including racemates, enantiomers, diastereomers and their mixtures) and their tautomers and salts are new. R = O, S or NH; R3 = alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, aryl or heteroaryl fused with 1-10C cycloalkyl, heterocyclyl, cycloalkyl, adamantyl, polycycloalkyl, alkenyl or alkynyl (all optionally substituted by one or more of halo, CN, NO2, NH2, OH, OR8, COOH, COOR8, OCOR8, NR8R9, NHCOR8, CONR8R9, SR8, SOR8, SO2R8, NHSO2R8, SO2NR8R9, CSNR8R9, NHCSR8, OSO2R8, SO2-OR8, aryl, heteroaryl, CHO, CF3, SCF3 or OCF3); R4 - R7 = H, halo, CN, NO2, NH2, OH, OR8, COOH, COOR8, OCOR8, NR8R9, NHCOR8, CONR8R9, NHCSR8, CSNR8R9, SR8, SOR8, SO2R8, NHSO2R8, SO2NR8R9, OSO2R8, SO2-OR8, CF3 or OCF3; or alkyl, alkoxy, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycyl, cycloalkyl, alkenyl, alkynyl, adamantyl or polycycloalkyl (all optionally substituted by one or more of halo, CN, NO2, NH2, OH, OR10, COOH, COOR10, OCOR10, NR10R11, NHCOR10, CONR10R11, NHCSR10, CSNR10R11, SR10, SOR10, SO2R10, NHSO2R10, SO2NR10R11, OSO2R10, SO2-OR10, aryl, heteroaryl, CHO, CF3 or OCF3); and R8 - R11 = H; or alkyl, aryl, alkenyl, alkynyl or heteroaryl (all optionally substituted by one or more of halo, alkyl, alkoxy, CN, NO2, NH2, OH, COOH, alkoxycarbonyl (no C-number given), CONH2, CHO, CF3 or OCF3). alkyl moieties have 1-6C unless specified otherwise. Independent claims are included for: (1) the preparation of (I); (2) the following specific new intermediates: 3-amino-6-chloro-1-tert. butoxycarbonyl-indazole, N-(6-chloro-1-tert. butoxycarbonyl-indazol-3-yl)-3-butenamide, 3-amino-6-chloro-1-((2-trimethylsilyl-ethoxy)-methyl)-indazole, N-((6-chloro-1-((2-trimethylsilyl-ethoxy)-methyl)-indazol-3-yl))-propanamide, N-((6-chloro-1-((2-trimethylsilyl-ethoxy)-methyl)-indazol-3-yl))-butanamide, N-((6-(3-pyridyl)-1-((2-trimethylsilyl-ethoxy)-methyl)-indazol-3-yl))-butanamide, N-(6-(3-pyridyl)-indazol-3-yl)-butanamide, N-((6-phenyl-1-((2-trimethylsilyl-ethoxy)-methyl)-indazol-3-yl))-butanamide, N-((6-(furan-3-yl)-1-((2-trimethylsilyl-ethoxy)-methyl)-indazol-3-yl))-butanamide, N-((6-(4-benzyloxy-phenyl)-1-((2-trimethylsilyl-ethoxy)-methyl)-indazol-3-yl))-butanamide, N-((6-(3,5-difluorophenyl)-1-((2-trimethylsilyl-ethoxy)-methyl)-indazol-3-yl))-butanamide and N-((6-(3-thienyl)-1-((2-trimethylsilyl-ethoxy)-methyl)-indazol-3-yl))-butanamide.
申请公布号 IL163831(D0) 申请公布日期 2005.12.18
申请号 IL20030163831 申请日期 2003.03.07
申请人 AVENTIS PHARMA S.A. 发明人
分类号 A61K31/416;A61K31/4196;A61K31/4439;A61K31/454;A61K31/497;A61K31/5377;A61K31/541;A61K31/69;A61K31/695;A61P3/00;A61P3/04;A61P3/10;A61P9/00;A61P9/10;A61P9/12;A61P15/00;A61P25/00;A61P25/02;A61P25/14;A61P25/16;A61P25/28;A61P35/00;A61P37/00;A61P37/04;C07D231/56;C07D401/04;C07D401/12;C07D405/04;C07D409/04;C07D409/12;C07F7/18 主分类号 A61K31/416
代理机构 代理人
主权项
地址